Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Cardiology, Medicine, Duke University 1998 - 2004
  • Medical Resident, Medicine, Duke University 1995 - 1998
  • M.D., Harvard University 1995
• 

  Previous Appointments & Affiliations

  • Associate Professor of Medicine, Medicine, Cardiology, Medicine 2014 - 2021
  • Assistant Professor of Medicine, Medicine, Cardiology, Medicine 2004 - 2014
  • Instructor, Temporary in the Department of Medicine, Medicine, Cardiology, Medicine 2004
• Research
• 

  Selected Grants

  • A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Subjects with Angina Pectoris Secondary 2019 - 2024
  • Direct Administration of AdVEGF-All6A+ LOI 2020 - 2022
  • DREAM-HF 2014 - 2021
  • Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction 2014 - 2021
  • A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients with Systolic Heart Failure 2017 - 2020
  • RECARDIO - REC-DUT-002 2018 - 2020
  • CD34+ Biologics 2018 - 2019
  • A Biomarker Study of the APEX-AMI and SOLSTICE Trial Populations 2016 - 2018
  • Aptamer-based affinity capture of circulating CAD EPCs awarded by National Institutes of Health 2013 - 2016
  • Adipose-derived regenerative cells in the Treatment of patients with chronic ischemic HEart disease Not Amenable to surgical or interventional revascularization 2014 - 2016
  • EPC Adhesion to Teflon-AF and ePTFE Vascular Grafts awarded by National Institutes of Health 1990 - 2013
  • REVEAL (Reduction of Infarct Expansion & Ventricular remodeling with Epo Admin after Large MI) awarded by National Institutes of Health 2005 - 2011
  • Assessing Circulating Progenitor Cells in Heart Disease awarded by National Institutes of Health 2006 - 2008
  • Blood pressure, endothelial cell dysfunction and outcomes in kidney disease awarded by National Institutes of Health 2008
• 

  External Relationships

  • AstraZeneca
  • Biocardia
  • Boehringer Ingleheim
  • Caladrius Biosciences
  • Covance
  • Novo Nordisk
  • Parexel
  • Recardio Inc
  • Sana Biotechnology Inc.
  • Veralox therapeutics
  • cytosorbents Inc
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Povsic, Thomas J., Ricardo Sanz-Ruiz, Andreu M. Climent, Roberto Bolli, Doris A. Taylor, Bernard J. Gersh, Philippe Menasché, et al. “Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies.” Esc Heart Fail 8, no. 3 (June 2021): 2306–9. https://doi.org/10.1002/ehf2.13256.
       Full Text  Link to Item
    • Januzzi, James L., John M. Canty, Saumya Das, Christopher R. DeFilippi, Gary A. Gintant, David E. Gutstein, Allan Jaffe, et al. “Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week.” J Am Coll Cardiol 77, no. 15 (April 20, 2021): 1922–33. https://doi.org/10.1016/j.jacc.2021.02.040.
       Full Text  Link to Item
    • Povsic, Thomas J., and Bernard J. Gersh. “Stem Cells in Cardiovascular Diseases: 30,000-Foot View.” Cells 10, no. 3 (March 9, 2021). https://doi.org/10.3390/cells10030600.
       Full Text  Link to Item
    • Povsic, Thomas J., Timothy D. Henry, and E Magnus Ohman. “Therapeutic Approaches for the No-Option Refractory Angina Patient.” Circ Cardiovasc Interv 14, no. 2 (February 2021): e009002. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009002.
       Full Text  Link to Item
    • Bartunek, Jozef, Andre Terzic, Beth A. Davison, Atta Behfar, Ricardo Sanz-Ruiz, Wojciech Wojakowski, Warren Sherman, et al. “Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes.” Esc Heart Fail 7, no. 6 (December 2020): 3345–54. https://doi.org/10.1002/ehf2.13031.
       Full Text  Link to Item
    • Makkar, Raj R., Dean J. Kereiakes, Frank Aguirre, Glenn Kowalchuk, Tarun Chakravarty, Konstantinos Malliaras, Gary S. Francis, et al. “Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial.” Eur Heart J 41, no. 36 (September 21, 2020): 3451–58. https://doi.org/10.1093/eurheartj/ehaa541.
       Full Text  Link to Item
    • Lewinski, Dirk von, Joseph B. Selvanayagam, Richard A. Schatz, Bernd Jilma, Jacek Kubica, Thomas J. Povsic, Darrell Nix, Stephan Henauer, Markus Wallner, and Markus REC-DUT-002 study group. “"Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial.” Trials 21, no. 1 (August 26, 2020): 744. https://doi.org/10.1186/s13063-020-04652-0.
       Full Text  Link to Item
    • Shavadia, Jay S., Christopher B. Granger, Wendimagegn Alemayehu, Cynthia M. Westerhout, Thomas J. Povsic, Sean Van Diepen, Christopher Defilippi, and Paul W. Armstrong. “Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.” J Am Heart Assoc 9, no. 13 (July 7, 2020): e016033. https://doi.org/10.1161/JAHA.120.016033.
       Full Text  Link to Item
    • Marquis-Gravel, Guillaume, Zhen Huang, Steven L. Zelenkofske, A Michael Lincoff, Roxana Mehran, P Gabriel Steg, Christoph Bode, John H. Alexander, and Thomas J. Povsic. “Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.” Am Heart J 223 (May 2020): 84–86. https://doi.org/10.1016/j.ahj.2020.02.013.
       Full Text  Link to Item
    • Shavadia, Jay S., Christopher B. Granger, Wendimagegn Alemayehu, Cynthia M. Westerhout, Thomas J. Povsic, Sorin J. Brener, Sean van Diepen, Christopher Defilippi, and Paul W. Armstrong. “High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.” Am Heart J 220 (February 2020): 137–44. https://doi.org/10.1016/j.ahj.2019.09.015.
       Full Text  Link to Item
    • Ward, Rachael, Zhen Huang, Frank W. Rockhold, Iris Baumgartner, Jeffrey S. Berger, Juuso I. Blomster, F Gerry R. Fowkes, et al. “Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.” Am Heart J 220 (February 2020): 51–58. https://doi.org/10.1016/j.ahj.2019.11.007.
       Full Text  Open Access Copy  Link to Item
    • Bittner, Vera A., Michael Szarek, Philip E. Aylward, Deepak L. Bhatt, Rafael Diaz, Jay M. Edelberg, Zlatko Fras, et al. “Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.” J Am Coll Cardiol 75, no. 2 (January 21, 2020): 133–44. https://doi.org/10.1016/j.jacc.2019.10.057.
       Full Text  Link to Item
    • Povsic, Thomas J., E Magnus Ohman, and C Michael Gibson. “Logistical Challenges Associated With Implementing Precision Medicine-Reply.” Jama Cardiol 4, no. 12 (December 1, 2019): 1301. https://doi.org/10.1001/jamacardio.2019.4175.
       Full Text  Link to Item
    • Roe, Matthew T., Qian H. Li, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, et al. “Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.” Circulation 140, no. 19 (November 5, 2019): 1578–89. https://doi.org/10.1161/CIRCULATIONAHA.119.042551.
       Full Text  Link to Item
    • Szarek, Michael, Ph Gabriel Steg, Dina DiCenso, Deepak L. Bhatt, Vera A. Bittner, Andrzej Budaj, Rafael Diaz, et al. “Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.” Circ Cardiovasc Qual Outcomes 12, no. 11 (November 2019): e005858. https://doi.org/10.1161/CIRCOUTCOMES.119.005858.
       Full Text  Link to Item
    • Goodman, Shaun G., Philip E. Aylward, Michael Szarek, Vakhtang Chumburidze, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, et al. “Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.” J Am Coll Cardiol 74, no. 9 (September 3, 2019): 1177–86. https://doi.org/10.1016/j.jacc.2019.07.015.
       Full Text  Link to Item
    • White, Harvey D., Ph Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Jay M. Edelberg, et al. “Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.” Eur Heart J 40, no. 33 (September 1, 2019): 2801–9. https://doi.org/10.1093/eurheartj/ehz299.
       Full Text  Link to Item
    • Ray, Kausik K., Helen M. Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L. Bhatt, Vera A. Bittner, Andrzej J. Budaj, et al. “Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.” Lancet Diabetes Endocrinol 7, no. 8 (August 2019): 618–28. https://doi.org/10.1016/S2213-8587(19)30158-5.
       Full Text  Link to Item
    • Normand, Camilla, David M. Kaye, Thomas J. Povsic, and Kenneth Dickstein. “Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology.” Lancet 393, no. 10175 (March 9, 2019): 1045–55. https://doi.org/10.1016/S0140-6736(18)32216-5.
       Full Text  Link to Item
    • Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.” Circulation 139, no. 7 (February 12, 2019): 863–73. https://doi.org/10.1161/CIRCULATIONAHA.118.037202.
       Full Text  Link to Item
    • Hernandez, Adrian F., Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel P. Jones, Lawrence A. Leiter, et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.” Lancet 392, no. 10157 (October 27, 2018): 1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.
       Full Text  Link to Item
    • Fanaroff, Alexander C., Valarie Morrow, Mitchell W. Krucoff, Jonathan H. Seltzer, Emerson C. Perin, Doris A. Taylor, Leslie W. Miller, et al. “A Path Forward for Regenerative Medicine.” Circ Res 123, no. 4 (August 3, 2018): 495–505. https://doi.org/10.1161/CIRCRESAHA.118.313261.
       Full Text  Link to Item
    • Henry, Timothy D., Douglas W. Losordo, Jay H. Traverse, Richard A. Schatz, E Marc Jolicoeur, Gary L. Schaer, Robert Clare, et al. “Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials.” Eur Heart J 39, no. 23 (June 14, 2018): 2208–16. https://doi.org/10.1093/eurheartj/ehx764.
       Full Text  Link to Item
    • Brilakis, Emmanouil S., Robert Edson, Deepak L. Bhatt, Steven Goldman, David R. Holmes, Sunil V. Rao, Kendrick Shunk, et al. “Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.” Lancet 391, no. 10134 (May 19, 2018): 1997–2007. https://doi.org/10.1016/S0140-6736(18)30801-8.
       Full Text  Link to Item
    • Povsic, Thomas J. “Approaching Regulatory Approval of Cardiovascular Regenerative Therapy.” Circ Res 122, no. 4 (February 16, 2018): 552–54. https://doi.org/10.1161/CIRCRESAHA.117.312520.
       Full Text  Link to Item
    • Henry, Timothy D., Thomas J. Povsic, and Douglas W. Losordo. “The (Translational) Road Less Traveled.” Circ Res 122, no. 2 (January 19, 2018): 207–9. https://doi.org/10.1161/CIRCRESAHA.117.311987.
       Full Text  Link to Item
    • Povsic, Thomas J. “Emerging Therapies for Congestive Heart Failure.” Clin Pharmacol Ther 103, no. 1 (January 2018): 77–87. https://doi.org/10.1002/cpt.913.
       Full Text  Link to Item
    • Chung, Matthew J., Jonathan D. Hansen, Ryan D. Schulteis, Joel C. Boggan, W Schuyler Jones, Thomas J. Povsic, Susan Roberts, Mitchell W. Krucoff, and Sunil V. Rao. “Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement.” Cardiovasc Revasc Med 18, no. 8 (December 2017): 588–91. https://doi.org/10.1016/j.carrev.2017.05.004.
       Full Text  Open Access Copy  Link to Item
    • Teerlink, John R., Marco Metra, Gerasimos S. Filippatos, Beth A. Davison, Jozef Bartunek, Andre Terzic, Bernard J. Gersh, et al. “Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.” Eur J Heart Fail 19, no. 11 (November 2017): 1520–29. https://doi.org/10.1002/ejhf.898.
       Full Text  Link to Item
    • Fernández-Avilés, Francisco, Ricardo Sanz-Ruiz, Andreu M. Climent, Lina Badimon, Roberto Bolli, Dominique Charron, Valentin Fuster, et al. “Global position paper on cardiovascular regenerative medicine.” Eur Heart J 38, no. 33 (September 1, 2017): 2532–46. https://doi.org/10.1093/eurheartj/ehx248.
       Full Text  Link to Item
    • Povsic, Thomas J., Rob Scott, Kenneth W. Mahaffey, Robert Blaustein, Jay M. Edelberg, Martin P. Lefkowitz, Scott D. Solomon, et al. “Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.” Cardiovasc Drugs Ther 31, no. 4 (August 2017): 445–58. https://doi.org/10.1007/s10557-017-6739-9.
       Full Text  Link to Item
    • Ohman, E Magnus, Matthew T. Roe, P Gabriel Steg, Stefan K. James, Thomas J. Povsic, Jennifer White, Frank Rockhold, et al. “Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.” Lancet 389, no. 10081 (May 6, 2017): 1799–1808. https://doi.org/10.1016/S0140-6736(17)30751-1.
       Full Text  Open Access Copy  Link to Item
    • Bartunek, Jozef, Andre Terzic, Beth A. Davison, Gerasimos S. Filippatos, Slavica Radovanovic, Branko Beleslin, Bela Merkely, et al. “Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.” Eur Heart J 38, no. 9 (March 1, 2017): 648–60. https://doi.org/10.1093/eurheartj/ehw543.
       Full Text  Link to Item
    • Chakravarty, Tarun, Raj R. Makkar, Deborah D. Ascheim, Jay H. Traverse, Richard Schatz, Anthony DeMaria, Gary S. Francis, et al. “ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design.” Cell Transplant 26, no. 2 (February 16, 2017): 205–14. https://doi.org/10.3727/096368916X692933.
       Full Text  Link to Item
    • Henry, Timothy D., Carl J. Pepine, Charles R. Lambert, Jay H. Traverse, Richard Schatz, Marco Costa, Thomas J. Povsic, et al. “The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction.” Catheter Cardiovasc Interv 89, no. 2 (February 1, 2017): 169–77. https://doi.org/10.1002/ccd.26601.
       Full Text  Link to Item
    • Welsh, Robert C., Matthew T. Roe, Philippe Gabriel Steg, Stefan James, Thomas J. Povsic, Christoph Bode, Charles Michael Gibson, and Erik Magnus Ohman. “Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100].” Am Heart J 184 (February 2017): 156. https://doi.org/10.1016/j.ahj.2017.01.004.
       Full Text  Link to Item
    • Povsic, Thomas J., Monica G. Lawrence, A Michael Lincoff, Roxana Mehran, Christopher P. Rusconi, Steven L. Zelenkofske, Zhen Huang, et al. “Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.” J Allergy Clin Immunol 138, no. 6 (December 2016): 1712–15. https://doi.org/10.1016/j.jaci.2016.04.058.
       Full Text  Link to Item
    • Welsh, Robert C., Matthew T. Roe, Philippe Gabriel Steg, Stefan James, Thomas J. Povsic, Christoph Bode, Charles Michael Gibson, and Erik Magnus Ohman. “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.” Am Heart J 181 (November 2016): 92–100. https://doi.org/10.1016/j.ahj.2016.08.008.
       Full Text  Link to Item
    • Povsic, Thomas J., Timothy D. Henry, Jay H. Traverse, F David Fortuin, Gary L. Schaer, Dean J. Kereiakes, Richard A. Schatz, et al. “The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.” Jacc Cardiovasc Interv 9, no. 15 (August 8, 2016): 1576–85. https://doi.org/10.1016/j.jcin.2016.05.003.
       Full Text  Link to Item
    • Povsic, Thomas J., and Andreas M. Zeiher. “IxCELL-DCM: rejuvenation for cardiac regenerative therapy?” Lancet 387, no. 10036 (June 11, 2016): 2362–63. https://doi.org/10.1016/S0140-6736(16)30138-6.
       Full Text  Link to Item
    • Povsic, Thomas J., and Douglas W. Losordo. “Getting Back to Normal: Can Enhanced Regeneration Maintain Health?” Circ Res 118, no. 12 (June 10, 2016): 1863–65. https://doi.org/10.1161/CIRCRESAHA.116.308936.
       Full Text  Link to Item
    • Nimjee, Shahid M., Thomas J. Povsic, Bruce A. Sullenger, and Richard C. Becker. “Translation and Clinical Development of Antithrombotic Aptamers.” Nucleic Acid Ther 26, no. 3 (June 2016): 147–55. https://doi.org/10.1089/nat.2015.0581.
       Full Text  Link to Item
    • Ganson, Nancy J., Thomas J. Povsic, Bruce A. Sullenger, John H. Alexander, Steven L. Zelenkofske, Jeffrey M. Sailstad, Christopher P. Rusconi, and Michael S. Hershfield. “Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.” J Allergy Clin Immunol 137, no. 5 (May 2016): 1610-1613.e7. https://doi.org/10.1016/j.jaci.2015.10.034.
       Full Text  Link to Item
    • Povsic, Thomas J., Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, and Charles Michael Gibson. “A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.” Am Heart J 174 (April 2016): 120–28. https://doi.org/10.1016/j.ahj.2016.01.004.
       Full Text  Link to Item
    • Lincoff, A. M., R. Mehran, and T. J. Povsic. “Erratum: On behalf of the REGULATE-PCI Investigators (Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomised clinical trial. (The Lancet (2016) 387 (34956)).” The Lancet 387, no. 10024 (March 19, 2016): 1162. https://doi.org/10.1016/S0140-6736(15)00399-2.
       Full Text
    • Povsic, Thomas J., Richard Sloane, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Harvey J. Cohen, and Miriam C. Morey. “Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study.” J Gerontol a Biol Sci Med Sci 71, no. 3 (March 2016): 362–69. https://doi.org/10.1093/gerona/glv180.
       Full Text  Link to Item
    • Fernandez, C. E., R. W. Yen, S. M. Perez, H. W. Bedell, T. J. Povsic, W. M. Reichert, and G. A. Truskey. “Human Vascular Microphysiological System for in vitro Drug Screening.” Sci Rep 6 (February 18, 2016): 21579. https://doi.org/10.1038/srep21579.
       Full Text  Open Access Copy  Link to Item
    • Bartunek, Jozef, Beth Davison, Warren Sherman, Thomas Povsic, Timothy D. Henry, Bernard Gersh, Marco Metra, et al. “Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design.” Eur J Heart Fail 18, no. 2 (February 2016): 160–68. https://doi.org/10.1002/ejhf.434.
       Full Text  Link to Item
    • Povsic, Thomas J. “Current State of Stem Cell Therapy for Ischemic Heart Disease.” Curr Cardiol Rep 18, no. 2 (February 2016): 17. https://doi.org/10.1007/s11886-015-0693-6.
       Full Text  Link to Item
    • Lincoff, A Michael, Roxana Mehran, Thomas J. Povsic, Steven L. Zelenkofske, Zhen Huang, Paul W. Armstrong, P Gabriel Steg, et al. “Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.” Lancet 387, no. 10016 (January 23, 2016): 349–56. https://doi.org/10.1016/S0140-6736(15)00515-2.
       Full Text  Link to Item
    • Henry, Timothy D., Gary L. Schaer, Jay H. Traverse, Thomas J. Povsic, Charles Davidson, Joon Sup Lee, Marco A. Costa, et al. “Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.” Cell Transplant 25, no. 9 (2016): 1701–11. https://doi.org/10.3727/096368916X691484.
       Full Text  Link to Item
    • Henry, Timothy D., and Thomas J. Povsic. “Repeat Cell Therapy for Refractory Angina: Déjà vu All Over Again?” Circ Cardiovasc Interv 8, no. 8 (August 2015). https://doi.org/10.1161/CIRCINTERVENTIONS.115.003049.
       Full Text  Link to Item
    • Patel, M. R., M. S. Conte, D. E. Cutlip, N. Dib, P. Geraghty, W. Gray, W. R. Hiatt, et al. “Erratum: Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC) (Journal of the American College of Cardiology (2015) 65:(931-41)).” Journal of the American College of Cardiology 65, no. 23 (June 16, 2015): 2578–79. https://doi.org/10.1016/j.jacc.2015.04.049.
       Full Text
    • Patel, Manesh R., Michael S. Conte, Donald E. Cutlip, Nabil Dib, Patrick Geraghty, William Gray, William R. Hiatt, et al. “Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).” J Am Coll Cardiol 65, no. 9 (March 10, 2015): 931–41. https://doi.org/10.1016/j.jacc.2014.12.036.
       Full Text  Link to Item
    • Povsic, Thomas J., Samuel Broderick, Kevin J. Anstrom, Linda K. Shaw, E Magnus Ohman, Eric L. Eisenstein, Peter K. Smith, and John H. Alexander. “Predictors of long-term clinical endpoints in patients with refractory angina.” J Am Heart Assoc 4, no. 2 (January 30, 2015). https://doi.org/10.1161/JAHA.114.001287.
       Full Text  Link to Item
    • Granger, Christopher B., and Thomas J. Povsic. “Another biomarker for risk assessment in acute myocardial infarction?” J Am Coll Cardiol 64, no. 16 (October 21, 2014): 1708–10. https://doi.org/10.1016/j.jacc.2014.06.1200.
       Full Text  Link to Item
    • Vavalle, J. P., C. P. Rusconi, S. Zelenkofske, W. A. Wargin, T. L. Ortel, J. H. Alexander, T. J. Povsic, and R. C. Becker. “The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.” J Thromb Thrombolysis 38, no. 3 (October 2014): 275–84. https://doi.org/10.1007/s11239-014-1081-6.
       Full Text  Link to Item
    • Povsic, Thomas J., John P. Vavalle, John H. Alexander, Laura H. Aberle, Steven L. Zelenkofske, Richard C. Becker, Christopher E. Buller, et al. “Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.” Eurointervention 10, no. 4 (August 2014): 431–38. https://doi.org/10.4244/EIJY14M06_01.
       Full Text  Link to Item
    • Al-Khatib, Sana M., Nancy M. Allen LaPointe, Ranee Chatterjee, Matthew J. Crowley, Matthew E. Dupre, David F. Kong, Renato D. Lopes, et al. “Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.” Ann Intern Med 160, no. 11 (June 3, 2014): 760–73. https://doi.org/10.7326/M13-1467.
       Full Text  Link to Item
    • Becker, R. C., M. Y. Chan, J. P. Vavalle, and T. J. Povsic. “Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor.” Drug Development Research 74, no. 8 (December 1, 2013): 510–16. https://doi.org/10.1002/ddr.21109.
       Full Text
    • Povsic, Thomas J., Richard Sloane, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Jennifer B. Green, Harvey J. Cohen, and Miriam C. Morey. “Lower levels of circulating progenitor cells are associated with low physical function and performance in elderly men with impaired glucose tolerance: a pilot substudy from the VA Enhanced Fitness trial.” J Gerontol a Biol Sci Med Sci 68, no. 12 (December 2013): 1559–66. https://doi.org/10.1093/gerona/glt067.
       Full Text  Link to Item
    • Vavalle, John P., Thomas J. Povsic, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Jaroslaw D. Kasprzak, Christoph Bode, et al. “Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial.” J Invasive Cardiol 25, no. 11 (November 2013): 593–99.
       Link to Item
    • Povsic, Thomas J., Samer S. Najjar, Kristi Prather, Jiying Zhou, Stacie D. Adams, Katherine L. Zavodni, Francine Kelly, et al. “EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.” J Thromb Thrombolysis 36, no. 4 (November 2013): 375–83. https://doi.org/10.1007/s11239-013-0944-6.
       Full Text  Link to Item
    • Jones, Lee W., Diane R. Fels, Miranda West, Jason D. Allen, Gloria Broadwater, William T. Barry, Lee G. Wilke, et al. “Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.” Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925–37. https://doi.org/10.1158/1940-6207.CAPR-12-0416.
       Full Text  Link to Item
    • Povsic, Thomas J., John P. Vavalle, Laura H. Aberle, Jaroslaw D. Kasprzak, Mauricio G. Cohen, Roxana Mehran, Christoph Bode, et al. “A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.” Eur Heart J 34, no. 31 (August 2013): 2481–89. https://doi.org/10.1093/eurheartj/ehs232.
       Full Text  Link to Item
    • Povsic, Thomas J., Candice Junge, Adel Nada, Richard A. Schatz, Robert A. Harrington, Charles J. Davidson, F David Fortuin, et al. “A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.” Am Heart J 165, no. 6 (June 2013): 854-861.e2. https://doi.org/10.1016/j.ahj.2013.03.003.
       Full Text  Link to Item
    • Becker, R. C., M. Y. Chan, J. P. Vavalle, and T. J. Povsic. “Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor.” Drug Development Research, 2013.
    • Say, Emil Anthony T., Alex Melamud, Denise Ann Esserman, Thomas J. Povsic, and Sai H. Chavala. “Comparative analysis of circulating endothelial progenitor cells in age-related macular degeneration patients using automated rare cell analysis (ARCA) and fluorescence activated cell sorting (FACS).” Plos One 8, no. 1 (2013): e55079. https://doi.org/10.1371/journal.pone.0055079.
       Full Text  Link to Item
    • Povsic, Thomas J., Richard Sloane, Jennifer B. Green, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Harvey J. Cohen, and Miriam C. Morey. “Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial.” J Diabetes Complications 27, no. 6 (2013): 633–36. https://doi.org/10.1016/j.jdiacomp.2013.08.004.
       Full Text  Link to Item
    • Povsic, Thomas J., Douglas W. Losordo, Kenneth Story, Candice E. Junge, Richard A. Schatz, Robert A. Harrington, and Timothy D. Henry. “Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.” Am Heart J 164, no. 5 (November 2012): 689-697.e3. https://doi.org/10.1016/j.ahj.2012.06.022.
       Full Text  Link to Item
    • Inrig, Jula K., Peter Van Buren, Catherine Kim, Wanpen Vongpatanasin, Thomas J. Povsic, and Robert Toto. “Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.” Clin J Am Soc Nephrol 7, no. 8 (August 2012): 1300–1309. https://doi.org/10.2215/CJN.10010911.
       Full Text  Link to Item
    • Povsic, Thomas J., Christopher M. O’Connor, Timothy Henry, Andrew Taussig, Dean J. Kereiakes, F David Fortuin, Alan Niederman, et al. “A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction.” Am Heart J 162, no. 4 (October 2011): 654-662.e1. https://doi.org/10.1016/j.ahj.2011.07.020.
       Full Text  Link to Item
    • Povsic, Thomas J., William A. Wargin, John H. Alexander, Joshua Krasnow, Merill Krolick, Mauricio G. Cohen, Roxana Mehran, et al. “Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.” Eur Heart J 32, no. 19 (October 2011): 2412–19. https://doi.org/10.1093/eurheartj/ehr179.
       Full Text  Link to Item
    • Losordo, Douglas W., Timothy D. Henry, Charles Davidson, Joon Sup Lee, Marco A. Costa, Theodore Bass, Farrell Mendelsohn, et al. “Intramyocardial, autologous CD34+ cell therapy for refractory angina.” Circ Res 109, no. 4 (August 5, 2011): 428–36. https://doi.org/10.1161/CIRCRESAHA.111.245993.
       Full Text  Link to Item
    • Inrig, Jula K., Peter Van Buren, Catherine Kim, Wanpen Vongpatanasin, Thomas J. Povsic, and Robert D. Toto. “Intradialytic hypertension and its association with endothelial cell dysfunction.” Clin J Am Soc Nephrol 6, no. 8 (August 2011): 2016–24. https://doi.org/10.2215/CJN.11351210.
       Full Text  Link to Item
    • Povsic, T. J., M. G. Cohen, M. Y. Chan, S. L. Zelenkofske, W. A. Wargin, R. A. Harrington, J. H. Alexander, C. P. Rusconi, and R. C. Becker. “Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.” J Thromb Thrombolysis 32, no. 1 (July 2011): 21–31. https://doi.org/10.1007/s11239-011-0588-3.
       Full Text  Link to Item
    • Najjar, Samer S., Sunil V. Rao, Chiara Melloni, Subha V. Raman, Thomas J. Povsic, Laura Melton, Gregory W. Barsness, et al. “Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.” Jama 305, no. 18 (May 11, 2011): 1863–72. https://doi.org/10.1001/jama.2011.592.
       Full Text  Link to Item
    • Povsic, Thomas J., Mauricio G. Cohen, Roxana Mehran, Christopher E. Buller, Christoph Bode, Jan H. Cornel, Jarosław D. Kasprzak, et al. “A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.” Am Heart J 161, no. 2 (February 2011): 261-268.e1-2. https://doi.org/10.1016/j.ahj.2010.10.022.
       Full Text  Link to Item
    • Povsic, Thomas J., Bruce A. Sullenger, Steven L. Zelenkofske, Christopher P. Rusconi, and Richard C. Becker. “Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.” J Cardiovasc Transl Res 3, no. 6 (December 2010): 704–16. https://doi.org/10.1007/s12265-010-9230-6.
       Full Text  Link to Item
    • Melloni, Chiara, Sunil V. Rao, Thomas J. Povsic, Laura Melton, Raymond J. Kim, Rakhi Kilaru, Manesh R. Patel, et al. “Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.” Am Heart J 160, no. 5 (November 2010): 795-803.e2. https://doi.org/10.1016/j.ahj.2010.09.007.
       Full Text  Link to Item
    • Povsic, Thomas J., Jiying Zhou, Stacie D. Adams, Michael P. Bolognesi, David E. Attarian, and Eric D. Peterson. “Aging is not associated with bone marrow-resident progenitor cell depletion.” J Gerontol a Biol Sci Med Sci 65, no. 10 (October 2010): 1042–50. https://doi.org/10.1093/gerona/glq110.
       Full Text  Link to Item
    • Lou, Junyang, Thomas J. Povsic, Jason D. Allen, Stacie D. Adams, Shelley Myles, Aijing Z. Starr, Thomas L. Ortel, and Richard C. Becker. “The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.” Thromb Res 126, no. 3 (September 2010): e175–79. https://doi.org/10.1016/j.thromres.2009.11.017.
       Full Text  Link to Item
    • Povsic, Thomas J., and Christopher M. O’Connor. “Cell therapy for heart failure: the need for a new therapeutic strategy.” Expert Rev Cardiovasc Ther 8, no. 8 (August 2010): 1107–26. https://doi.org/10.1586/erc.10.99.
       Full Text  Link to Item
    • Becker, Richard C., Thomas Povsic, Mauricio G. Cohen, Christopher P. Rusconi, and Bruce Sullenger. “Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.” Thromb Haemost 103, no. 3 (March 2010): 586–95. https://doi.org/10.1160/TH09-10-0716.
       Full Text  Link to Item
    • Povsic, T. J., B. A. Sullenger, S. L. Zelenkofske, C. P. Rusconi, and R. C. Becker. “Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine.” Journal of Cardiovascular Translational Research, 2010, 1–13.
    • Stroncek, John D., Bryan S. Grant, Melissa A. Brown, Thomas J. Povsic, George A. Truskey, and William M. Reichert. “Comparison of endothelial cell phenotypic markers of late-outgrowth endothelial progenitor cells isolated from patients with coronary artery disease and healthy volunteers.” Tissue Eng Part A 15, no. 11 (November 2009): 3473–86. https://doi.org/10.1089/ten.TEA.2008.0673.
       Full Text  Link to Item
    • Povsic, Thomas J., Stacie D. Adams, Katherine L. Zavodni, Francine Kelly, Laura G. Melton, Sunil V. Rao, Samer S. Najjar, Robert A. Harrington, and Eric D. Peterson. “Aldehyde dehydrogenase activity allows reliable EPC enumeration in stored peripheral blood samples.” J Thromb Thrombolysis 28, no. 3 (October 2009): 259–65. https://doi.org/10.1007/s11239-009-0306-6.
       Full Text  Link to Item
    • Povsic, Thomas J., Katherine L. Zavodni, Enrikas Vainorius, Jennifer F. Kherani, Pascal J. Goldschmidt-Clermont, and Eric D. Peterson. “Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations.” Am Heart J 157, no. 2 (February 2009): 335–44. https://doi.org/10.1016/j.ahj.2008.10.010.
       Full Text  Link to Item
    • Mills, James S., Colleen Stack N’diaye, Eric Yow, Mark Urtz, Thomas J. Povsic, Joseph C. Greenfield, and Harry R. Phillips. “Preliminary observations using optical coherence tomography to assess neointimal coverage of a metal stent in a porcine model.” Cardiovasc Revasc Med 10, no. 4 (2009): 229–35. https://doi.org/10.1016/j.carrev.2008.11.003.
       Full Text  Link to Item
    • Zhu, Shoukang, Sarah Evans, Bin Yan, Thomas J. Povsic, Victor Tapson, Pascal J. Goldschmidt-Clermont, and Chunming Dong. “Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells.” Circulation 118, no. 21 (November 18, 2008): 2156–65. https://doi.org/10.1161/CIRCULATIONAHA.108.787200.
       Full Text  Link to Item
    • Povsic, Thomas J., and Pascal J. Goldschmidt-Clermont. “Endothelial progenitor cells: markers of vascular reparative capacity.” Ther Adv Cardiovasc Dis 2, no. 3 (June 2008): 199–213. https://doi.org/10.1177/1753944708093412.
       Full Text  Link to Item
    • Povsic, Thomas J., Katherine L. Zavodni, Francine L. Kelly, Shoukang Zhu, Pascal J. Goldschmidt-Clermont, Chunming Dong, and Eric D. Peterson. “Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity.” J Am Coll Cardiol 50, no. 23 (December 4, 2007): 2243–48. https://doi.org/10.1016/j.jacc.2007.08.033.
       Full Text  Link to Item
    • Povsic, Thomas J., and Eric D. Peterson. “Stem cells for the ischaemic heart.” Expert Opin Biol Ther 6, no. 5 (May 2006): 427–42. https://doi.org/10.1517/14712598.6.5.427.
       Full Text  Link to Item
    • Povsic, Thomas J., and Eric D. Peterson. “Progenitor cell therapy of ischemic heart disease: the new frontier.” Future Cardiol 1, no. 1 (January 2005): 87–98. https://doi.org/10.1517/14796678.1.1.87.
       Full Text  Link to Item
    • Povsic, Thomas J., Trudy A. Kohout, and Robert J. Lefkowitz. “Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis.” J Biol Chem 278, no. 51 (December 19, 2003): 51334–39. https://doi.org/10.1074/jbc.M309968200.
       Full Text  Link to Item
    • Gallo, R. L., M. Ono, T. Povsic, C. Page, E. Eriksson, M. Klagsbrun, and M. Bernfield. “Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds.” Proc Natl Acad Sci U S A 91, no. 23 (November 8, 1994): 11035–39. https://doi.org/10.1073/pnas.91.23.11035.
       Full Text  Link to Item
    • Povsic, T. J., S. A. Strobel, and P. B. Dervan. “Sequence-Specific Double-Strand Alkylation and Cleavage of DNA Mediated by Triple-Helix Formation.” Journal of the American Chemical Society 114, no. 15 (July 1, 1992): 5934–41. https://doi.org/10.1021/ja00041a005.
       Full Text
    • Povsic, T. J., and P. B. Dervan. “Sequence-Specific Alkylation of Double-Helical DNA by Oligonucleotide-Directed Triple-Helix Formation.” Journal of the American Chemical Society 112, no. 25 (January 1, 1990): 9428–30. https://doi.org/10.1021/ja00181a075.
       Full Text
    • Povsic, T. J., and P. B. Dervan. “Triple helix formation by oligonucleotides on DNA extended to the physiological pH range.” Journal of the American Chemical Society 111, no. 8 (January 1, 1989): 3059–61. https://doi.org/10.1021/ja00190a047.
       Full Text

  • Book Sections

    • Povsic, T. J. “Mesenchymal Stem Cells for Treatment of Peripheral Vascular Disease.” In Regenerative Medicine for Peripheral Artery Disease, 43–70, 2016. https://doi.org/10.1016/B978-0-12-801344-1.00004-8.
       Full Text

  • Conference Papers

    • Johnson, Grace L., Timothy D. Henry, Thomas J. Povsic, Douglas W. Losordo, Ross F. Garberich, Larissa I. Stanberry, Craig E. Strauss, and Jay H. Traverse. “CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina.” In Stem Cells Transl Med, 9:1147–52, 2020. https://doi.org/10.1002/sctm.20-0046.
       Full Text  Link to Item
    • Povsic, Thomas J., E Magnus Ohman, Matthew T. Roe, Jennifer White, Frank W. Rockhold, Gilles Montalescot, Jan H. Cornel, et al. “P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.” In Jama Cardiol, 4:680–84, 2019. https://doi.org/10.1001/jamacardio.2019.1510.
       Full Text  Open Access Copy  Link to Item
    • Melloni, Chiara, Karen P. Alexander, Angie Wu, W Schuyler Jones, Rajendra H. Mehta, Robert W. Harrison, David Kong, et al. “Type 2 Myocardial Infarction: Incidence, Risk Factors, and Outcomes Among 41,581 Patients Enrolled in 3 Large Randomized Clinical Trials.” In Circulation, Vol. 140, 2019.
       Link to Item
    • Shavadia, Jay S., Christopher B. Granger, Wendimagegn W. Alemayehu, Cynthia M. Westerhout, Sean Van Diepen, Thomas J. Povsic, Christopher Defillipi, and Paul W. Armstrong. “High Throughput Targeted Proteomics Discovery Approach to Discover Novel Biomarkers Associated With St-segment Resolution After an St Elevation Myocardial Infarction.” In Circulation, Vol. 140, 2019.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.